Go Pro
NYSE:BLCO

Bausch + Lomb (BLCO) Stock Price, News & Analysis

Bausch + Lomb logo
$16.79 -0.12 (-0.72%)
Closing price 03:59 PM Eastern
Extended Trading
$16.75 -0.04 (-0.23%)
As of 04:46 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

About Bausch + Lomb Stock (NYSE:BLCO)

Advanced

Key Stats

Today's Range
$16.55
$17.11
50-Day Range
$14.87
$17.23
52-Week Range
$13.53
$18.92
Volume
429,056 shs
Average Volume
434,726 shs
Market Capitalization
$5.99 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$18.75
Consensus Rating
Hold

Company Overview

Bausch + Lomb Corporation operates as an eye health company in the United States, Puerto Rico, China, France, Japan, Germany, the United Kingdom, Canada, Russia, Spain, Italy, Mexico, Poland, South Korea, and internationally. It operates in three segments: Vision Care, Pharmaceuticals, and Surgical. The Vision Care segment provides contact lens that covers the spectrum of wearing modalities, including daily disposable and frequently replaced contact lenses; and contact lens care products comprising over-the-counter eye drops, eye vitamins, and mineral supplements that address various conditions, such as eye allergies, conjunctivitis, dry eye, and redness relief. Its Pharmaceuticals segment offers proprietary and generic pharmaceutical products for post-operative treatments, as well as for the treatment of glaucoma, eye inflammation, ocular hypertension, dry eyes, and retinal diseases. The Surgical segment provides medical device equipment, consumables, and technologies for the treatment of cataracts, corneal, vitreous, and retinal eye conditions; and intraocular lenses and delivery systems, phacoemulsification equipment, and other surgical instruments and devices for cataract surgery. The company sells its products and services through direct sales forces and independent distributors. Bausch + Lomb Corporation was founded in 1853 and is headquartered in Vaughan, Canada. Bausch + Lomb Corporation is a subsidiary of Bausch Health Companies Inc.

Bausch + Lomb Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
71st Percentile Overall Score

BLCO MarketRank™: 

Bausch + Lomb scored higher than 71% of companies evaluated by MarketBeat, and ranked 307th out of 893 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    Bausch + Lomb has received a consensus rating of Hold. The company's average rating score is 2.29, and is based on no strong buy ratings, 5 buy ratings, 8 hold ratings, and 1 sell rating.

  • Upside Potential

    Bausch + Lomb has a consensus price target of $18.75, representing about 12.6% upside from its current price of $16.66.

  • Amount of Analyst Coverage

    Bausch + Lomb has only been the subject of 4 research reports in the past 90 days.

  • Read more about Bausch + Lomb's stock forecast and price target.
  • Earnings Growth

    Earnings for Bausch + Lomb are expected to grow by 29.27% in the coming year, from $0.82 to $1.06 per share.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of Bausch + Lomb is -34.71, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of Bausch + Lomb is -34.71, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Earnings Growth Ratio

    Bausch + Lomb has a PEG Ratio of 0.52. PEG Ratios below 1 indicate that a company could be undervalued.

  • Price to Book Value per Share Ratio

    Bausch + Lomb has a P/B Ratio of 0.91. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

  • Percentage of Shares Shorted

    1.08% of the float of Bausch + Lomb has been sold short.
  • Short Interest Ratio / Days to Cover

    Bausch + Lomb has a short interest ratio ("days to cover") of 10.26, which indicates bearish sentiment.
  • Change versus previous month

    Short interest in Bausch + Lomb has recently decreased by 4.64%, indicating that investor sentiment is improving.
  • Dividend Yield

    Bausch + Lomb does not currently pay a dividend.

  • Dividend Growth

    Bausch + Lomb does not have a long track record of dividend growth.

  • News Sentiment

    Bausch + Lomb has a news sentiment score of 0.31. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.72 average news sentiment score of Healthcare companies.
  • News Coverage This Week

    MarketBeat has tracked 18 news articles for Bausch + Lomb this week, compared to 4 articles on an average week.
  • Search Interest

    Only 1 people have searched for BLCO on MarketBeat in the last 30 days. This is a decrease of -67% compared to the previous 30 days.
  • MarketBeat Follows

    1 people have added Bausch + Lomb to their MarketBeat watchlist in the last 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, Bausch + Lomb insiders have not sold or bought any company stock.

  • Percentage Held by Insiders

    1.45% of the stock of Bausch + Lomb is held by insiders.

  • Percentage Held by Institutions

    11.07% of the stock of Bausch + Lomb is held by institutions.

  • Read more about Bausch + Lomb's insider trading history.
Receive BLCO Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Bausch + Lomb and its competitors with MarketBeat's FREE daily newsletter.

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

BLCO Stock News Headlines

Bausch + Lomb Earnings Call Signals Growing Momentum
Bausch + Lomb (NYSE:BLCO) Research Coverage Started at UBS Group
Trump Takes Emergency Action - Plus Elon Musk's New Venture
Elon Musk has quietly launched a new venture - one that has nothing to do with rockets, EVs, or Neuralink. Trump has issued emergency support to accelerate the rollout, and it's already live in multiple states. The Financial Times reports Sam Altman is personally calling people to build this for OpenAI. A few little-known companies control the entire supply chain - meaning anyone who wants access must go through them. Their stocks are available to buy right now.tc pixel
Bausch + Lomb: Q2 Earnings Snapshot
Bausch & Lomb Corp (BLCO) Q2 2026 Earnings
See More Headlines

BLCO Stock Analysis - Frequently Asked Questions

Bausch + Lomb's stock was trading at $17.07 at the beginning of the year. Since then, BLCO shares have decreased by 2.4% and is now trading at $16.6550.

Bausch + Lomb Corporation (NYSE:BLCO) posted its quarterly earnings results on Wednesday, April, 29th. The company reported $0.08 earnings per share for the quarter, topping analysts' consensus estimates of $0.06 by $0.02. Bausch + Lomb's revenue for the quarter was up 9.4% compared to the same quarter last year.
Read the conference call transcript
.

Bausch + Lomb (BLCO) raised $788 million in an initial public offering on Friday, May 6th 2022. The company issued 35,000,000 shares at $21.00-$24.00 per share.

Top institutional shareholders of Bausch + Lomb include Handelsbanken Fonder AB (0.01%) and FNY Investment Advisers LLC. Insiders that own company stock include Brent L Saunders, Sam Eldessouky and A Robert D Bailey.
View institutional ownership trends
.

Shares of BLCO stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that Bausch + Lomb investors own include PayPal (PYPL), Meta Platforms (META), Tesla (TSLA), Advanced Micro Devices (AMD), Walt Disney (DIS), Intel (INTC) and Devon Energy (DVN).

Company Calendar

Last Earnings
4/29/2026
Today
8/03/2026
Fiscal Year End
12/31/2026

Industry, Sector and Symbol

Stock Exchange
NYSE
Industry
Healthcare Equipment & Supplies
Sub-Industry
Healthcare Supplies
Current Symbol
NYSE:BLCO
CIK
1860742
Fax
N/A
Employees
13,000
Year Founded
1853

Price Target and Rating

High Price Target
$21.00
Low Price Target
$16.00
Potential Upside/Downside
+11.7%
Consensus Rating
Hold
Rating Score (0-4)
2.29
Research Coverage
14 Analysts

Profitability

EPS (Trailing Twelve Months)
($0.48)
Trailing P/E Ratio
N/A
Forward P/E Ratio
20.47
P/E Growth
0.52
Net Income
-$360 million
Net Margins
-3.21%
Pretax Margin
-1.22%
Return on Equity
4.14%
Return on Assets
1.93%

Debt

Debt-to-Equity Ratio
0.79
Current Ratio
1.55
Quick Ratio
1.02

Sales & Book Value

Annual Sales
$5.32 billion
Price / Sales
1.13
Cash Flow
$1.66 per share
Price / Cash Flow
10.14
Book Value
$18.40 per share
Price / Book
0.91

Miscellaneous

Outstanding Shares
357,057,000
Free Float
351,880,000
Market Cap
$5.99 billion
Optionable
Optionable
Beta
0.56

Social Links

Options Trading Made Easy - Download Now Cover

Learn the basics of options trading and how to use them to boost returns and manage risk with this free report from MarketBeat. Click the link below to get your free copy.

Get This Free Report

This page (NYSE:BLCO) was last updated on 8/3/2026 by MarketBeat.com Staff.
From Our Partners